• Skip to main content
  • Skip to footer
cnb1439_3rs-project_nav-ad_v2
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Press releases

September 5, 2023

CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

Partnership to provide customers with direct access to portfolio of highly characterized hepatic cells to recreate advanced Liver-on-a-Chip

Category iconPress releases

August 30, 2023

CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

Cambridge, UK, 30th August 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ

Category iconPress releases

June 6, 2023

CN Bio appoints Dr. Samantha Macro as Chief Financial Officer

Cambridge, UK, 06 June 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological

Category iconPress releases

March 14, 2023

CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

Cambridge, UK, 14 March 2023: CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological

Category iconPress releases

February 27, 2023

CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

Cambridge, UK, CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS),

Category iconPress releases

January 17, 2023

The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

Cambridge, UK, 17th January 2023: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ

Category iconPress releases

December 19, 2022

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and services. Former CEO, Dr

Category iconPress releases

July 19, 2022

CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities

State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services Cambridge,

Category iconPress releases

May 24, 2022

CN Bio appoints Dr Paul Brooks as Chief Business Officer

Cambridge, UK, 24 May 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ

Category iconPress releases

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio adds computational modelling capabilities to ADME services for enhanced bioavailability profiling September 1, 2025
  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
Cyber Essentials Logo